Korea Ocean Research and Development Institute

Korea Institute of Ocean Science & Technology

Korea Ocean Research Institute

Pulmuwon Food Co., Ltd.

Il Chan Kim

Joung Han Yim

Se Jong Han

Hyoung Seok Lee

Tai Kyoung Kim

Ha Ju Park

Pil-Sung Kang

Heeyong Park

Doc Kyu Kim

Sung Jin Kim

Mi Ra Park

Hyun Cheol Oh

Dong-Gyu Jo

Jung Eun Kim

Cheolsoon Lee

Sung Gu Lee

Yu-Kyung Park

Pyung Cheon Lee

Bhattarai Hari Datta

Hari Datta Bhattarai

Keun-Sik Kim

Dockyu Kim

Sang Youn Lee

Chang Woon Choi

Hong Kum Lee

Su-Geun Yang

Lee Don Hang

Suhkneung Pyo

Babita Paudel-Bhattarai

Seung Jin Kim

Soon Gyu Hong

Keun Sik Kim

Hye Yeon Koh

Yoo Kyung Lee

Paudel Babita

Yu-Kyeong Park

Jong Han Yim

The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen, and more specifically to a pharmaceutical composition containing Ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (iNOS) in the transcription stage to significantly inhibit the production of nitric oxide (NO) that is a key mediator of inflammatory responses. In addition, it inhibits the activation of the inflammatory mediator NF-&#x3ba;B, inhibits p38 MAPK, ERK1/2 and JNK signaling pathways, and inhibits the expression of the LPS receptor TLR4, suggesting that Ramalin has an excellent anti-inflammatory effect. Thus, the composition containing Ramalin can be effectively used to fundamentally treat or prevent inflammatory diseases or immune diseases and to relieve or alleviate the symptoms of the diseases.

Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin

There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived fromaccording to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis.

Pharmaceutical composition for preventing or treating hepatic fibrosis and cirrhosis containing ramalin

Disclosed is a method of the synthesis of ramalin. It comprises reacting a glutamic acid derivative, which is prepared using alkylchloroformate, with a hydrazine salt compound, which is prepared from hydroxy aniline, whether protected or not. The synthesis method allows ramalin, excellent in antioxidant and anti-inflammatory activity, to be simply synthesized at stable yield even without use of a highly toxic solvent such as DMF. In addition, the method is cost competitive, and provides ramalin at high efficiency, thus enabling the mass production of ramalin.

Method for synthesizing ramalin and ramalin precursor by using glutamic acid derivative and hydroxy aniline or hydroxy aniline having protected hydroxy group

The present invention relates to a method for synthesizing ramalin, and more particularly to a method for synthesizing ramalin, which comprises allowing 2-hydrazinylphenol to react with L-glutamic acid having a protected carboxyl group at C-1 and a protected amino group at C-2, and a method for preventing decomposition of the ramalin. According to the present invention, ramalin having excellent antioxidant and anti-inflammatory activities can be synthesized in high yield, and thus can be produced in large amounts. In addition, ramalin can be stably maintained for a long period of time, and thus can be easily used for industrial purposes.

Method for preparing ramalin

The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.

Pharmaceutical and food compositions for preventing or treating diabetes or obesity

The present invention relates to a novel compound having excellent antioxidant activity, isolated from, and more particularly to a novel compound, RAMALIN&#x2122;, having excellent antioxidant activity, isolated from the Antarctic lichen, a method for preparing the RAMALIN&#x2122;, and a pharmaceutical composition, a functional food and a functional cosmetic composition, which contain the RAMALIN&#x2122; as an active ingredient. The RAMALIN&#x2122; according to the invention has significantly excellent antioxidant effects compared to commercially available antioxidants, and thus can be widely used in agents for treating oxidation-related diseases, anti-aging functional foods, functional cosmetic products for skin whitening and wrinkle reduction, etc.

Compound ramalin and use thereof

A process for manufacturing a health-supplementary food containing aloe as an active ingredient, including, in the order recited, the steps of washing aloe, fresh leaf vegetables including kale, root vegetables including carrot, and fruit including tomato thoroughly with water; pulverizing from 70 to 85 wt. % of aloe, from 10 to 20 wt. % of leaf vegetables including kale, from 5 to 15 wt. % of root vegetables and fruit including, respectively, carrot and tomato, into pieces having a length of 2 cm or less using a chopper to provide a pulverized mixture; mixing sugar with the pulverized mixture to provide a sugar concentration for the mixture of from 15 to 37.5 Brix; innoculating the mixture with from 2 to 5% by weight of a starter per 100% by weight of total starting materials, the starter having been cultured from a strain of Lactobacillus family grown in an MRS medium, in a fermenter at a temperature ranging from 20.degree. to 35.degree. C.; fermenting the mixture for from 48 to 96 hours, stopping fermentation when the mixture has a pH ranging from 3.2 to 3.7; squeezing the mixture using a press to obtain a fermented liquid, admixing additional sugar with the fermented liquid until homogenized to maintain the sugar concentration at a range of from 50 to 60 Brix; and aging the mixture at room temperature for several months.

Process for manufacturing a health-supplementary food containing aloe as

Growing community of inventors

Seoul, South Korea

Il Chan Kim